Published March 22, 2026 · Parkinson's Lawsuit Help
Syngenta's April 2025 settlement framework is the single most important development in the paraquat litigation since MDL 3004 was created. Federal paraquat Parkinson's cases are consolidated in Multidistrict Litigation No. 3004, In re: Paraquat Products Liability Litigation, before Chief Judge Nancy J. Rosenstengel in the Southern District of Illinois. Thousands of cases are pending. A parallel mass tort program operates in the Philadelphia Court of Common Pleas before Judge Joshua Roberts, currently hosting approximately 1,799 active paraquat cases. In April 2025 Syngenta announced a settlement framework covering a substantial portion of the U.S. inventory; in January 2026 the first Philadelphia bellwether case settled confidentially on the courthouse steps. In March 2026 Syngenta announced it would discontinue U.S. production of paraquat. The framework structures resolution of a large portion of the federal MDL inventory but leaves significant questions open for Pennsylvania state court claimants, Chevron-only claims, and late-filed cases.
What the framework actually does
The Syngenta framework creates a qualified settlement fund administered through court-supervised allocation. Claimants who opt in waive their right to a jury trial and accept compensation determined by a points-based matrix that weighs factors such as documented exposure history, age at diagnosis, severity of Parkinson's symptoms, comorbid conditions, and the strength of differential diagnosis. The framework does not extinguish Chevron's potential liability.
Who qualifies
Eligibility generally turns on (1) documented occupational paraquat exposure, (2) a Parkinson's disease diagnosis from a qualified neurologist using standard movement disorder criteria, and (3) the absence of disqualifying differential diagnoses. Mixers, loaders, applicators, farmworkers, and crop-dusting pilots are the core eligible categories. Residential-drift claimants may qualify with additional documentation.
Why Pennsylvania state court claimants may recover more
Pennsylvania state court claimants are widely expected to recover more, on average, than federal MDL claimants. Three reasons: (1) Pennsylvania's consent-by-registration jurisdiction law — upheld after the U.S. Supreme Court declined to hear Syngenta's challenge in October 2025 — permits suits in Pennsylvania even against foreign defendants who registered to do business in the state; (2) Philadelphia juries have a long track record of higher verdicts in pharmaceutical and toxic tort cases than typical federal MDL bellwethers; and (3) the Philadelphia Complex Litigation Center moves cases on a faster trial schedule than the MDL, which gives plaintiffs leverage in settlement negotiations. For a claimant whose facts are strong, opting out of a federal framework and prosecuting in Philadelphia can yield a materially higher recovery — but it requires both eligibility for Pennsylvania jurisdiction and counsel willing to try the case.
Settlement timing
Court-administered settlement programs typically operate on fixed registration windows. Late registration is not guaranteed even with attorney intervention. If you have not consulted with counsel about a paraquat Parkinson's claim, the most consequential action you can take this month is a free case review to confirm eligibility and preserve your timing.
Talking to your lawyer about opt-out strategy
If your case is eligible for both the federal framework and Pennsylvania state court, your attorney should walk you through the trade-offs: speed of payment versus expected recovery, certainty versus jury risk, and how the structure of your specific exposure history fits each forum. Cookie-cutter answers are a red flag.
Get a free case review
If you or a family member were exposed to paraquat and have been diagnosed with Parkinson's disease, request a free case review. It takes 15 to 30 minutes by phone, costs nothing, and locks in your place while settlement options remain open. Check eligibility or call (717) 724-7503.